Search This Blog

Friday, February 27, 2026

PMV plans Q1 2027 NDA filing for rezatapopt in platinum-resistant ovarian cancer after Phase 1

 

 

  • New England Journal of Medicine publishes Phase 1 PYNNACLE first-in-human rezatapopt data in TP53 Y220C-mutated advanced solid tumors.
  • Phase 1 findings support a registrational Phase 2 strategy in platinum-resistant/refractory ovarian cancer.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)